Aurobindo gets USFDA nod for generic ImitrexBS Reporter / Mumbai February 1, 2008Aurobindo Pharma has received the US Food & Drug Administration (FDA) nod to market sumatriptan succinate in the United States. The acute migraine and headache drug, which will come out in the 25mg, 50mg and 100mg tablet forms, is an identical version of GlaxoSmithKline's (GSK) Imitrex.According to an IMS Health data, annual sales of the formulation in the US were approximately $950 million in 2007.This is Aurobindo's 63rd abbreviated new drug application (ANDA) approval from the USFDA.GSK had settled patent litigations with Ranbaxy Laboratories and Dr Reddy
